1. The Value of Anti-angiogenics in Multiple Myeloma Therapy
   Thomas Moehler et al, 2019, Tumor Angiogenesis CrossRef
2. Impact of increased access to novel agents on the survival of multiple myeloma patients treated at a single New Zealand centre
   Barry D. Hock et al, 2019, Internal Medicine Journal CrossRef
3. From guidelines to real world: results from the National Multiple Myeloma Registry in Uruguay on 222 newly diagnosed multiple myeloma patients from 2012 to 2015
   E. Riva et al, 2019, Current Medical Research and Opinion CrossRef
4. Frontline treatment patterns and attrition rates by subsequent lines of therapy in patients with newly diagnosed multiple myeloma
   Rafael Fonseca et al, 2020, BMC Cancer CrossRef
5. Survival Outcomes of Newly Diagnosed Multiple Myeloma at a Tertiary Care Center in North India (IMAGe: 001A Study)
   Uday Yanamandra et al, 2021, JCO Global Oncology CrossRef
6. Management of Patients with Relapsed and/or Refractory Multiple Myeloma Treated with Novel Combination Therapies in Routine Clinical Practice in Germany
   H. Tilman Steinmetz et al, 2022, Advances in Therapy CrossRef
7. Usability of German hospital administrative claims data for healthcare research: General assessment and use case of multiple myeloma in Munich university hospital in 2015–2017
   Amal AlZahmi et al, 2022, PLOS ONE CrossRef
8. The results of therapy of patients with multiple myeloma in real clinical practice (results of a multicenter study)
   Yu. A. Zabolotneva et al, 2024, Meditsinskiy sovet = Medical Council CrossRef
9. The Value of Anti-Angiogenics in Multiple Myeloma Therapy
   Thomas Moehler et al, 2017, Tumor Angiogenesis CrossRef
10. The Myeloma Landscape in Australia and New Zealand: The First 8 Years of the Myeloma and Related Diseases Registry (MRDR)
    Krystal Bergin et al, 2021, Clinical Lymphoma Myeloma and Leukemia CrossRef